Exelixis
EXEL
Market cap $12.2B

44.86 USD

-0.31

0.69%

At close Jul 11, 4:00 PM EDT

After hours

44.79

-0.07

0.16%

1 day

-0.69%

5 days

-2.58%

1 month

8.28%

3 months

27.05%

6 months

27.08%

Year to date

32.17%

1 year

98.94%

5 years

88.01%

10 years

1,083.64%

About: Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Employees: 1,147

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 10 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

125% more call options, than puts

Call options by funds: $77.7M | Put options by funds: $34.5M

79% more first-time investments, than exits

New positions opened: 100 | Existing positions closed: 56

25% more repeat investments, than reductions

Existing positions increased: 212 | Existing positions reduced: 169

11% more capital invested

Capital invested by funds: $8.33B [Q4 2024] → $9.27B (+$942M) [Q1 2025]

11% more funds holding in top 10

Funds holding in top 10: 9 [Q4 2024] → 10 (+1) [Q1 2025]

7% more funds holding

Funds holding: 514 [Q4 2024] → 549 (+35) [Q1 2025]

2.22% more ownership

Funds ownership: 87.53% [Q4 2024] → 89.75% (+2.22%) [Q1 2025]

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$38

15%

downside

Avg. target

$49

8%

upside

High target

$60

34%

upside

10 analyst ratings

7 positive

70%

3 neutral

30%

0 negative

0%

Barclays Peter Lawson	11%downside $40	Equal-Weight Maintained	10 Jul 2025
HC Wainwright & Co. Robert Burns	18%upside $53	Buy Maintained	30 Jun 2025
Stephens & Co. Sudan Loganathan	34%upside $60	Overweight Upgraded	24 Jun 2025
Truist Securities Asthika Goonewardene	23%upside $55	Buy Reiterated	23 Jun 2025
JMP Securities Silvan Tuerkcan	11%upside $50	Market Outperform Maintained	23 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 25 articles about EXEL published over the past 30 days

Zacks Investment Research

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Zacks Investment Research

Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks

Top-ranked stocks Urban Outfitters (URBN), Fox (FOX), Electronic Arts (EA), Uber Technologies (UBER) and Exelixis (EXEL) are likely to beat on the bottom line in their upcoming releases.

Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks

Zacks Investment Research

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Zacks Investment Research

Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?

EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.

Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?

Zacks Investment Research

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

The Motley Fool

2 Stocks to Buy With Less Than $50

One formula to generate strong returns on equity markets involves investing small amounts of money in top stocks regularly over long periods. Buying fractional shares is one way to apply this strategy, but it's also possible to find attractive corporations at already-affordable prices.

2 Stocks to Buy With Less Than $50

Zacks Investment Research

EXEL or ARGX: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

EXEL or ARGX: Which Is the Better Value Stock Right Now?

Zacks Investment Research

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

The Motley Fool

3 No-Brainer Stocks to Buy for Under $100 Right Now

What's the biggest misconception about investing? The idea that you need a lot of money to get started is certainly a contender.

3 No-Brainer Stocks to Buy for Under $100 Right Now

Zacks Investment Research

3 Stocks With Upgraded Broker Ratings to Consider for Solid Returns

EXEL, LYFT and KGC have all seen notable broker upgrades recently. Here???s why they may offer solid returns ahead.

3 Stocks With Upgraded Broker Ratings to Consider for Solid Returns

See News Rankings

Charts implemented using Lightweight Charts™